Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Evolent Health Inc (NYSE: EVH) closed the day trading at $8.95 up 0.34% from the previous closing price of $8.92. In other words, the price has increased by $0.34 from its previous closing price. On the day, 2.2 million shares were traded. EVH stock price reached its highest trading level at $9.105 during the session, while it also had its lowest trading level at $8.71.
Ratios:
For a better understanding of EVH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.01 and its Current Ratio is at 1.01. In the meantime, Its Debt-to-Equity ratio is 1.21 whereas as Long-Term Debt/Eq ratio is at 0.99.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Needham on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
On December 03, 2024, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $36 to $29.
Stephens Downgraded its Overweight to Equal-Weight on November 08, 2024, whereas the target price for the stock was revised from $38 to $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when Holder Diane bought 2,735 shares for $9.33 per share. The transaction valued at 25,518 led to the insider holds 70,584 shares of the business.
McCarthy Daniel Joseph bought 11,040 shares of EVH for $99,470 on Mar 06 ’25. The PRESIDENT now owns 389,004 shares after completing the transaction at $9.01 per share. On Mar 07 ’25, another insider, Jelinek Richard M, who serves as the Director of the company, bought 30,000 shares for $9.12 each. As a result, the insider paid 273,750 and bolstered with 15,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 1037941632 and an Enterprise Value of 1968939648. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.48 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 0.897 whereas that against EBITDA is 27.253.
Stock Price History:
The Beta on a monthly basis for EVH is 0.68, which has changed by -0.6835219 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $29.58, while it has fallen to a 52-week low of $7.06. The 50-Day Moving Average of the stock is -3.99%, while the 200-Day Moving Average is calculated to be -8.63%.
Shares Statistics:
Over the past 3-months, EVH traded about 3.11M shares per day on average, while over the past 10 days, EVH traded about 3837120 shares per day. A total of 115.94M shares are outstanding, with a floating share count of 114.24M. Insiders hold about 2.78% of the company’s shares, while institutions hold 107.98% stake in the company. Shares short for EVH as of 1757894400 were 23098110 with a Short Ratio of 7.44, compared to 1755216000 on 20289592. Therefore, it implies a Short% of Shares Outstanding of 23098110 and a Short% of Float of 20.16.
Earnings Estimates
A comprehensive evaluation of Evolent Health Inc (EVH) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.12, with high estimates of $0.22 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.38 and $0.03 for the fiscal current year, implying an average EPS of $0.22. EPS for the following year is $0.62, with 11.0 analysts recommending between $0.92 and $0.41.
Revenue Estimates
14 analysts predict $473.74M in revenue for . The current quarter. It ranges from a high estimate of $555M to a low estimate of $458.94M. As of . The current estimate, Evolent Health Inc’s year-ago sales were $621.4MFor the next quarter, 14 analysts are estimating revenue of $482.03M. There is a high estimate of $590.9M for the next quarter, whereas the lowest estimate is $466.2M.
A total of 14 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $2.08B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $2.55BBased on 14 analysts’ estimates, the company’s revenue will be $2.41B in the next fiscal year. The high estimate is $2.61B and the low estimate is $2.29B.
